BCL2 and glioblastoma: Astrocyte-GBM interactions via gap junctions or secreted factors increase NF-κB, JAK/STAT and MAPK/JNK signaling, resulting in increased BCL-2 and IAP expression and reduced BAX and consequent resistance to radiation and chemotherapy [93–99].